Abstract Information

First Name: Youssef Last Name: Anouar Email: Youssef.Anouar@univ-rouen.fr Address: Univ. Rouen Normandy, INSERM, Nordic, U1239, F-76000 Rouen France Participation: symposium Title of the Symposium: Emerging effectors in neurodegeneration: from preclinical to clinical mode Category: Academic/Researcher Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applications.	
Email: Youssef.Anouar@univ-rouen.fr Address: Univ. Rouen Normandy, INSERM, Nordic, U1239, F-76000 Rouen France Participation: symposium Title of the Symposium: Emerging effectors in neurodegeneration: from preclinical to clinical mode Category: Academic/Researcher Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applications.	
Address: Univ. Rouen Normandy, INSERM, Nordic, U1239, F-76000 Rouen France symposium Title of the Symposium: Emerging effectors in neurodegeneration: from preclinical to clinical mode Category: Academic/Researcher Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applic	
Participation: symposium Title of the Symposium: Emerging effectors in neurodegeneration: from preclinical to clinical mode Category: Academic/Researcher Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applications.	
Title of the Symposium: Emerging effectors in neurodegeneration: from preclinical to clinical mode Category: Academic/Researcher Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applications.	ance
Category: Academic/Researcher Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applications and the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: therapeutic applications are provided by the pathophysiology of PD: the pat	
Thematic Area: Neurodegeneration, Neuroplasticity, and Repair Role of a selenoprotein in the pathophysiology of PD: therapeutic appli	nodels
Title: Role of a selenoprotein in the pathophysiology of PD: therapeutic applications and the pathophysiology of PD: therapeutic applications are also as the pathophysiology of PD: therapeutic applications are also as the pathophysiology of PD: therapeutic applications are also as the pathophysiology of PD: therapeutic applications are also as the pathophysiology of PD: therapeutic applications are also as the pathophysiology of PD: therapeutic applications are also as the pathophysiology of PD: the pa	
Title.	
administration	pplication after intranasal
administration	
Co-Authors: Univ. Rouen Normandy, INSERM, Nordic, U1239, F-76000 Rouen France	ance

Abstract:

Oxidative stress is central to the pathogenesis of different diseases affecting the central nervous system, but therapeutic strategies targeting this pathological process have been difficult to design. We have previously demonstrated that selenoprotein T (SELENOT), a new thioredoxin-like protein of the ER, is essential for embryonic development and dopaminergic neuron survival and function. SELENOT exerts its neuroprotective activity by reducing oxidative stress and improving tyrosine hydroxylase activity. In an animal model of PD, targeted SELENOT gene disruption in the brain provoked rapid and severe parkinsonian-like motor deficits. Based on these findings, we designed a 10-amino acid peptide named PSELT as a potential mimic of SELENOT catalytic site to test its activity in PD animal models. PSELT proved to be efficient in protecting dopaminergic neurons in vitro and in vivo and could improve motor skills in animal models of PD. Transcriptomics studies revealed that PSELT acts through an original epigenetic regulatory mechanism. These results uncover the role of SELENOT as a neuroprotective enzyme and indicate that PSELT is a new therapeutic candidate for treatment of neurodegenerative diseases.